Senecavirus A (SVA) and Foot-and-Mouth Disease Virus (FMDV) are significant viral pathogens that cause major economic losses in livestock, particularly in pigs and cattle. This study investigates the inhibitory effects of bovine lactoferricin-lactoferrampin (bLFcin-LFamp) peptides on SVA and FMDV, delivered through recombinant Lactobacillus oral treatment in mice. The peptides' antiviral activity was evaluated in vitro and in vivo, with Lactobacillus engineered to express bLFcin-LFamp as a delivery vehicle. The results demonstrated that the recombinant Lactobacillus significantly reduced viral replication and clinical symptoms in mice infected with both SVA and FMDV. This study suggests that bLFcin-LFamp peptides, when delivered via oral Lactobacillus treatment, represent a promising therapeutic strategy for controlling viral infections in livestock.